Insider Selling: Hemostemix Inc. (CVE:HEM) Director Sells 332,500 Shares of Stock

Hemostemix Inc. (CVE:HEM) Director Thomas Smeenk sold 332,500 shares of the company’s stock in a transaction that occurred on Tuesday, October 8th. The shares were sold at an average price of C$0.07, for a total value of C$21,612.50. Following the completion of the transaction, the director now directly owns 93 shares in the company, valued at C$6.05. The trade was a 0.00 % decrease in their position.

Thomas Smeenk also recently made the following trade(s):

• On Wednesday, August 21st, Thomas Smeenk bought 2,000 shares of Hemostemix stock. The stock was acquired at an average cost of C$0.04 per share, for a total transaction of C$80.00.

Hemostemix Price Performance

Shares of HEM opened at C$0.06 on Friday. The company has a market capitalization of C$5.23 million, a price-to-earnings ratio of -3.00 and a beta of 0.15. The business has a 50-day moving average of C$0.07 and a 200-day moving average of C$0.06. Hemostemix Inc. has a 1 year low of C$0.04 and a 1 year high of C$0.11.

Hemostemix Company Profile

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.